Functional Outcomes After Hyaluronic Acid Injections Following Arthroscopy

Daewoong Group Indonesia9 enrolled

Overview

The goal of this study is to investigate the effect of hyaluronic acid injection on functional recovery and pain control in patients following knee or shoulder arthroscopy.

The study consists of three main periods: screening, treatment, and follow-up. During the screening period, subjects will provide written informed consent and undergo screening assessments. Only those who meet all inclusion criteria and none of the exclusion criteria will be enrolled in the study. During the treatment period, before completing the arthroscopy procedure, 10 mL of Hyaluronic Acid 0.5% (CG Synovia) will be injected into the joint cavity through the existing arthroscopy portal using a suitable needle attached to a Luer lock. The joint will then be moved through its full range of motion to ensure proper distribution of the product within the joint. During the follow-up period, subjects will attend visits up to 24 weeks after treatment, specifically at 4 weeks (Visit 3), 12 weeks (Visit 4), and 24 weeks (Visit 5) for evaluation.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Arthroscopic Surgery

Interventions

CG Synovia (Hyaluronic Acid 0.5%)DEVICE

After arthroscopic procedure, attach a suitable needle to the Luer Lock and inject 10ml of CG Synovia into the joint cavity through a portal already placed in the joint for arthroscopy. Move the joint through full range of motion to allow CG Synovia to distribute throughout the joint, synovium, and joint surfaces.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male and female adults aged 18 to 60 years at the date of the written informed consent form. 2. Patient with surgery scheduled for arthroscopic procedure on knee or shoulder. 3. Those who could understand the provided information and were able to fill out the questionnaire. 4. Those who voluntarily decided to participate in the study and wrote the informed consent form. Exclusion Criteria: 1. In the following cases that may affect test results 1. Patients with history and suspected of rheumatoid arthritis (RA). 2. Patients with osteoarthritis in the joint related to specific joint movement. 3. Those with a history of surgery in the related area of the join that affect join movement. 4. Patients with infection at the surgical site. 2. Patients with chronic diseases that may affect surgery, such as uncontrolled diabetes or uncontrolled high blood pressure. 3. Patients with complex regional pain syndrome. 4. If adverse reactions are expected during surgery in the following cases: 1. People taking blood coagulants or patients with diseases that require blood coagulants. 2. When there are restrictions on the use of anticoagulants or antithrombotic agents. 3. Those with confirmed severe liver dysfunction or decreased renal function. 4. Patients with other serious systemic diseases such as severe anemia. 5. Known HIV positive person receiving medication. 5. Patients are allergic to substances used in medical devices for the study (Hyaluronic Acid). 6. Pregnant, lactating, or women of childbearing potential who are unwilling to use contraception during the study. 7. Use of drugs or medical devices due to participation in other study 8. Other people deemed inappropriate to participate in the test by the investigator (including high probability of noncompliance).

Locations (2)

Siloam Hospitals Mampang

Jakarta, Indonesia

MRCCC Siloam Hospitals Semanggi

Jakarta, Indonesia

Outcomes

Primary Outcomes

Safety Evaluation

Safety evaluation will be measured by monitoring the Adverse Events (AE)

Time frame: 4, 12 and 24 weeks

Change from baseline to 4 weeks in Haemoglobin concentration

Haemoglobin concentration count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : g/dL

Time frame: 4 weeks

Change from baseline to 4 weeks in Haematocrit

Haematocrit count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : %

Time frame: 4 weeks

Change from baseline to 4 weeks in White Blood Cell (WBC) count

White Blood Cell (WBC) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit 10³/µL

Time frame: 4 weeks

Change from baseline to 4 weeks in Platelet count

Platelet count count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : 10³/µL

Time frame: 4 weeks

Change from baseline to 4 weeks in Basophils (differential)

Basophils (differential) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : %

Time frame: 4 weeks

Change from baseline to 4 weeks in Eosinophils (differential)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Eosinophils (differential) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : %

Change from baseline to 4 weeks in Neutrophils (differential)

Neutrophils (differential) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : %

Time frame: 4 weeks

Change from baseline to 4 weeks in Lymphocytes (differential)

Lymphocytes (differential) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : %

Time frame: 4 weeks

Change from baseline to 4 weeks in Monocytes (differential)

Monocytes (differential) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : %

Time frame: 4 weeks

Change from baseline to 4 weeks in Random Blood Glucose

Random Blood Glucose count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : mg/dL

Time frame: 4 weeks

Change from baseline to 4 weeks in Urea

Urea count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : mg/dL

Time frame: 4 weeks

Change from baseline to 4 weeks in Creatinine

Creatinine count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : mg/dL

Time frame: 4 weeks

Change from baseline to 4 weeks in Aspartate aminotransferase (AST)

Aspartate aminotransferase (AST) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : U/L

Time frame: 4 weeks

Change from baseline to 4 weeks in Alanine aminotransferase (ALT)

Alanine aminotransferase (ALT) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : U/L

Time frame: 4 weeks

Change from baseline to 4 weeks in Prothrombin time (PT)

Prothrombin Time (PT) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : Seconds

Time frame: 4 weeks

Change from baseline to 4 weeks in Activated partial thromboplastin time (aPTT)

Activated Partial Thromboplastin Time (aPTT) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : Seconds

Time frame: 4 weeks

Change from baseline to 4 weeks in International normalised ratio (INR)

International Normalised Ratio (INR) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : Ratio

Time frame: 4 weeks

Change from baseline to Weeks 4, 12, and 24 in active knee flexion range of motion

Active knee flexion ROM (degrees) will be measured in the operated knee using a standard goniometer during clinical examination. Higher values indicate greater joint mobility. Unit : degrees